TechandBio
3月前
This is one of the most undervalued stocks on the market. An aquas based drug manufacturing platform that will disrupt the chemical plants manufacturing business. This stock can see 100.00+ sooner than you can imagine. Think Catelent 2.0
Chart will see 10.00-20.00+in the coming months or sooner and looking for an all time break and blue sky breakout past the $42.00 mark.
This stock will create serious wealth for investors! The first time in history a company enzymatically made a drug CDXS synthetically made Novartis Leqvio® (inclisiran) 4 distinct ways Purer Cleaner and higher Yields at a fraction of the price of A "phosphorus chemical plant's
This is a next level technology play if you do your homework 1 metric ton to 30 metric tons growth from today to 2030 3000% growth CDXS looks to capture 15% of that Tam looking to make 1.5 Billion in revenue growing in the coming years. they have a revenue generating business today and have multiple big pharma contracts that are being finalized my guess Novartis and Alnylam for their Eco Synthesis partner CDMO partnership where they will be able to scale Kilo Size batches. Right now they are making thousands of dollars per gram of RNAI drugs.
They can plug and play this disruptive technology process to any modality of medicines! Think about that for a minute!
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics
November 14, 2024 4:05 pm EST
—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company’s double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company’s rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform and establish Codexis’ position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.
Codexis Demonstrates First-ever Enzymatic Synthesis of Approved siRNA Therapeutic.
During an oral Spotlight Presentation, Codexis unveiled the successful end-to-end enzymatic synthesis of an entire approved RNAI therapeutic asset, inclisiran. Codexis enzymatically synthesized the full-length sense and antisense strands of the molecule, including the enzymatic incorporation of a tissue-targeting moiety to the sense strand. To date, this process has only been completed utilizing phosphoramidite chemistry, a process that involves the use of harsh chemical conditions and vast amounts of toxic organic solvents. By contrast, Codexis’ ECO Synthesis manufacturing platform operates under milder, aqueous conditions, that improves product quality and dramatically decreases chemical waste production.
In addition to this fully enzymatic route of synthesis, the Company demonstrated similar outcomes utilizing three routes of enzymatic ligation to produce the siRNA therapeutic asset, combining oligonucleotide fragments made by sequential enzymatic synthesis and traditional phosphoramidite chemistry. Key data from the presentation include:
Achieved incorporation efficiency of >98% during sequential enzymatic oligo synthesis
Successfully attached the tri-GalNAc tissue-targeting moiety by enzymatic ligation
Obtained full-length oligonucleotides of equal quality and yields, using ligation of short fragments made with enzymes or by traditional phosphoramidite chemistry
Now that Codexis has successfully achieved this unprecedented milestone, the Company will continue to optimize its process for robustness, scaled-up quantities and improved purity with the goal of providing customers with siRNA material of comparable or better quality to phosphoramidite chemistry
CEO Dilly has sold his last 2 companies for multi billions. I believe he will get 5-10 Billion for CDXS!
$CDXS
King Bolaba
7年前
Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization
February 15, 2018 | About: CDXS +0%
REDWOOD CITY, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Shawn Clairmont to the newly created position of Senior Director, Molecular Diagnostics. Codexis is expanding into the molecular diagnostics industry by developing and commercializing high-performance enzymes for use in next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) applications. Clairmont will be responsible for all commercial activities related to the molecular diagnostics enzyme product line, including product launches and market and pricing strategies. She reports to Michael Aldridge, Codexis’ Senior VP Corporate & Strategic Development.
“We welcome Shawn to Codexis as we prepare to commercially launch our first high-performance enzymes for the molecular diagnostics industry,” said Aldridge. “Shawn brings us significant global experience in product launches and commercial account management as well as established relationships with key molecular diagnostic firms and industry opinion leaders. We look forward to calling upon her expertise in developing successful strategies as we bring new enzymes into this established market.”
Warning! GuruFocus has detected 6 Warning Signs with CDXS. Click here to check it out.
CDXS 30-Year Financial Data
The intrinsic value of CDXS
Peter Lynch Chart of CDXS
“This is an exciting time in molecular diagnostics as new technologies, such as liquid biopsy, create the need for high-performance enzymes,” said Clairmont. “Codexis is uniquely positioned to use its CodeEvolver® protein engineering platform to develop enzymes aimed at improving the sensitivity and precision of these tests in identifying biomarkers of interest. I’m delighted to join the Codexis team.”
Clairmont has 13 years of molecular diagnostics industry experience. Most recently she served as Chief Operating Officer of BRIDGenomics, a molecular diagnostics and medical device marketing consultancy providing business development and strategic marketing expertise. She previously served for eight years at the molecular diagnostics company QIAGEN in a variety of positions with increasing responsibility, most recently as Director of Sales, America, on the Global Advanced Molecular Pathology Team. Prior to QIAGEN, Clairmont was a technical marketing representative and account manager at bioArray Solutions LTD. She holds an MBA from the College of Saint Scholastica in Duluth, Minn. and a BA in biology from Saint Olaf College in Northfield, Minn.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
King Bolaba
7年前
Codexis Reports Financial Results for the Third Quarter of 2017
Nov. 9, 2017 4:05 PM
Product sales increase 71% over the prior year
Affirms 2017 revenue guidance
Conference call begins at 4:30 pm Eastern time today
REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2017, and provides a business update.
“We continue to deliver excellent results in 2017, highlighted by the creation of our new partnership with Nestlé Health Science, as well as a solid financial performance,” said Codexis President and CEO John Nicols. “Our recently announced strategic collaboration with Nestlé Health Science validates the use of our CodeEvolver® protein engineering technology platform for biotherapeutic drug discovery and demonstrates our ability to partner with yet another of the world’s leading companies. Regarding the third quarter financial results, once again we are most proud of the growth in product sales, which increased 71% for the third quarter and 73% year-to-date, with gross margin on product sales again toward the high end of our guidance range.
“Collaboration efforts with Nestlé Health Science have already begun and are expected to contribute significantly to our fourth quarter revenues,” he added. “Together with continued strength in product sales, our fourth quarter is set up to produce the highest revenue quarter for the year and we are reaffirming our total revenue guidance for 2017 of $50 million to $53 million. Delivering on our 2017 revenue guidance will be an exceptional accomplishment by the Codexis team, especially given that over $20 million of last year’s revenues were from non-recurring milestone payments and deferred revenues related to the completion of our two pharmaceutical partners’ platform license technology transfers. The new 2017 revenue sources that offset those headwinds continue to gain momentum as we end this year, setting us up for double-digit revenue growth in 2018.”
Third Quarter Financial Highlights
Total revenues for the third quarter of 2017 were $10.0 million compared with $14.9 million for the third quarter of 2016. The prior year period included the recognition of an $8.0 million milestone payment and $0.6 million in deferred revenue under the platform licensing deal with Merck. Product sales for the third quarter of 2017 increased 71% to $6.9 million from $4.1 million for the prior-year period, primarily due to higher demand for enzymes. Research and development service revenues for the third quarter of 2017 were $2.9 million compared with $10.4 million for the third quarter of 2016, which included $8.6 million of revenue from Merck described above. Revenue from the revenue-sharing arrangement with Exela PharmSci for sales of the argatroban injectable drug was $0.1 million for the third quarter of 2017 compared with $0.4 million for third quarter of 2016.
Gross margin on product sales for the third quarter of 2017 increased to 43% from 32% for the third quarter of 2016, mainly due to an increase in sales of higher-margin products.
Research and development (R&D) expenses were $8.1 million for the third quarter of 2017 compared with $5.5 million for the third quarter of 2016, with the increase due primarily to higher outside services expense related to CDX-6114, our lead candidate for the treatment of phenylketonuria (PKU), and increased costs associated with higher headcount, partially offset by the absence of amortization of intangibles. Selling, general and administrative (SG&A) expenses for the third quarter of 2017 were $8.0 million compared with $5.2 million for the third quarter of 2016, due primarily to an increase in legal fees and increased costs associated with higher headcount, partially offset by lower depreciation expense.
Net loss for the third quarter of 2017 was $10.2 million, or $0.21 per share, compared with net income for the third quarter of 2016 of $1.4 million, or $0.04 per basic share and $0.03 per diluted share. Non-GAAP net loss for the third quarter of 2017 was $8.2 million, or $0.17 per share, compared with non-GAAP net income for the third quarter of 2016 of $4.0 million, or $0.10 per basic share and $0.09 per diluted share. A reconciliation of GAAP to non-GAAP measures is provided below.
Year-to-date Financial Results
Total revenues for the nine months ended September 30, 2017 were $28.3 million compared with $38.9 million for the first nine months of 2016. The prior year period included the recognition of $20.4 million in milestone payments and deferred revenue from platform licensing deals with GSK and Merck. Total revenues for the first nine months of 2017 included $19.1 million in product sales, $8.3 million in R&D revenue and $0.8 million from the revenue-sharing arrangement with Exela.
Gross margin on product sales for the first nine months of 2017 was 44% compared with 33% for the first nine months of 2016, due to an increase in sales of higher-margin products.
R&D expenses for the first nine months of 2017 were $20.2 million compared with $16.3 million for the first nine months of 2016, with the increase primarily due to higher outside service fees related to CDX-6114 and increased costs associated with higher headcount. SG&A expenses for the first nine months of 2017 were $21.1 million compared with $18.5 million for the prior-year period, primarily due to an increase in legal expenses and increase in costs associated with higher headcount, partially offset by lower depreciation expense.
Net loss for the first nine months of 2017 was $24.0 million, or $0.53 per share, compared with a net loss for the first nine months of 2016 of $3.3 million, or $0.08 per share. Non-GAAP net loss for the first nine months of 2017 was $18.0 million, or $0.39 per share, compared with non-GAAP net income for the first nine months of 2016 of $4.5 million, or $0.11 per basic and diluted share.
Cash and cash equivalents as of September 30, 2017 were $23.8 million, compared with $19.2 million as of December 31, 2016.
Financial Outlook
Codexis affirms financial guidance for 2017, as follows:
Total revenues of $50 million to $53 million, which includes revenue from the Nestlé Health Science strategic collaboration announced in October 2017.
Product sales are expected to be between $25 million and $27 million, reflecting an increase of 63% to 76% over 2016.
Gross margin on product sales is expected to be between 40% and 43%.
Codexis expects fourth quarter operating expenses, which is the combined total of R&D and SG&A expenses, to be approximately $16 million, which is higher than our previous forecast due mainly to higher legal expenses. The guidance assumes expenses associated with the company’s accelerated development activities to initiate human trials for CDX-6114 in early 2018.
Non-GAAP Financial Measures
Consolidated financial information has been presented in accordance with GAAP as well as on a non-GAAP basis. On a non-GAAP basis, financial measures exclude non-cash items such as depreciation expense, intangible asset amortization expense and stock-based compensation expense. Non-GAAP financial measures presented are: non-GAAP net income or loss, non-GAAP net income or loss per share (basic and diluted), and non-GAAP operating expenses, including non-GAAP research and development expense and non-GAAP selling, general and administrative expense. Non-GAAP operating expenses exclude stock-based compensation expense, amortization of intangible assets and depreciation of fixed assets.
Codexis management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an ongoing basis, and internally for operating, budgeting and financial planning purposes. Codexis management believes the non-GAAP information is useful for investors by offering them the ability to identify trends in what management considers to be Codexis’ core operating results and to better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of expense that affect Codexis. These non-GAAP financial measures are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP, and therefore these non-GAAP results should only be used for evaluation in conjunction with the corresponding GAAP measures. A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table entitled “Reconciliation of GAAP to Non-GAAP Financial Measures.”
Conference Call and Webcast
Codexis will hold a conference call and audio webcast today beginning at 4:30 p.m. Eastern time. A slide presentation featuring an updated chart of the company’s product pipeline to accompany the conference call commentary is available on the Investors section of the company’s website at www.codexis.com. The conference call dial-in numbers are 855-890-8665 for domestic callers and 720-634-2938 for international callers, and the passcode is 5797258. A live webcast of the call will be available on the Investors section of www.codexis.com.
A recording of the call will be available for 48 hours beginning approximately two hours after the completion of the call by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers. Please use the passcode 5797258 to access the recording. A webcast replay will be available on the Investors section of www.codexis.com for 30 days, beginning approximately two hours after the completion of the call.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Codexis’ expectations regarding fourth quarter 2017 and 2017 total revenues, product sales, gross margin on product sales, and operating expenses, 2018 revenue growth, and its anticipated timeline to initiate human trials for CDX-6114 and associated expenditures. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; Codexis’ dependence on a limited number of products and customers in its biocatalysis business; potential adverse effects to Codexis’ business if its customers’ pharmaceutical or food products are not received well in the markets; risks, uncertainties and costs associated with the successful development of biotherapeutic candidates, including obtaining development partners for its biotherapeutic programs and progressing such programs to clinical trials and regulatory approvals; Codexis’ ability to develop and commercialize new products for the biocatalysis markets; Codexis’ dependence on a limited number of contract manufacturers for large-scale production of its enzymes; Codexis’ ability to deploy its technology platform in new market spaces, including the fine chemicals, therapeutics and in vitro molecular diagnostics markets; Codexis’ ability to comply with the terms of its credit facility and its associated debt service obligations; Codexis’ need for additional capital in the future in order to expand its business or to adjust for market conditions or strategic considerations, which may involve Codexis entering into equity offerings, debt financings, credit facilities and/or strategic collaborations; Codexis’ dependence on key personnel; risks associated with the patent litigation that Codexis initiated in February 2016; Codexis’ ability to establish and maintain adequate protection for intellectual property, trade secrets and other proprietary rights covering its technologies; and any claims by third parties that Codexis is infringing their intellectual property rights or other proprietary rights. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 9, 2017 and Form 10-Q filed August 9, 2017, including under the caption “Risk Factors” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Codexis Contacts:
Investors
LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com
Financial Tables to Follow
Codexis, Inc.
Condensed Consolidated Statements of Opera
stocktrademan
9年前
$CDXS recent news/filings
bullish 3.85
bull flag continuation
## source: finance.yahoo.com
Mon, 30 Nov 2015 13:40:00 GMT ~ New Information Reveals Opportunity in Volatility - Research on Strongbridge Biopharma, Pacific Mercantile Bancorp, Codexis and Exa Corp
[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 30, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Strongbridge ...
read full: http://finance.yahoo.com/news/information-reveals-opportunity-volatility-research-134000165.html
*********************************************************
Thu, 26 Nov 2015 21:20:25 GMT ~ Breeze-Eastern Corp (BZC): Are Hedge Funds Right About This Stock?
read full: http://www.insidermonkey.com/blog/breeze-eastern-corp-bzc-are-hedge-funds-right-about-this-stock-390476/
*********************************************************
Tue, 24 Nov 2015 22:44:03 GMT ~ Is Southern National Banc. of Virginia, Inc (SONA) A Good Stock To Buy?
read full: http://www.insidermonkey.com/blog/is-southern-national-banc-of-virginia-inc-sona-a-good-stock-to-buy-386529/
*********************************************************
Tue, 24 Nov 2015 14:30:02 GMT ~ The Zacks Analyst Blog Highlights: Integrated Device Technology, ZAGG, MRV Communications, Codexis and Gigamon
read full: http://finance.yahoo.com/news/zacks-analyst-blog-highlights-integrated-143002671.html
*********************************************************
Tue, 24 Nov 2015 12:23:04 GMT ~ Codexis to Present at LD Micro Main Event
[at noodls] - REDWOOD CITY, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces that management will ...
read full: http://www.noodls.com/view/731A58404F4EAD3FEA7CBBC2C682CB3E4E60D1D0
*********************************************************
$CDXS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CDXS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CDXS/company-info
Ticker: $CDXS
OTC Market Place: Not Available
CIK code: not found
Company name: Codexis, Inc.
Incorporated In:
Business Description:
$CDXS share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$CDXS extra dd links
Company name: Codexis, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CDXS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CDXS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CDXS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/news - http://finance.yahoo.com/q/h?s=CDXS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CDXS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CDXS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CDXS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Codexis%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Codexis%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Codexis%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CDXS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CDXS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CDXS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CDXS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CDXS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CDXS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CDXS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CDXS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CDXS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CDXS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CDXS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CDXS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CDXS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CDXS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CDXS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CDXS
$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
TrendTrade2016
3月前
Monksdream
6月前
Pisd
7月前
PennyStock Alert
5年前
MadCityCyclone
6年前
